Compare Trip.com Group Ltd (TCOM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs BIO-TECHNE Corp — how do they compare? Trip.com Group Ltd trades at $43.78 (market cap $28.12B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Trip.com Group Ltd is far larger — about 2.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.45%). Which is the better fit depends on your goals.
| TCOM | TECH | |
|---|---|---|
Market Cap | $28.12B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $72.12 |
52-Week Low | $39.84 | $43.31 |
Enterprise Value | $20.82B | $11.24B |
Dividend Yield | 0.42% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
